The University of Toronto (U of T) has announced a new collaboration with Janssen Inc. to develop therapies for neurological diseases, including mood disorders and neurodegenerative diseases. The collaborative project, called Neuroscience Catalyst, was facilitated by Johnson and Johnson Innovation Center in California, and will help identify and support promising early stage discoveries that can be advanced into the clinic. U of T is co-funding the project, and is forming a joint steering committee with Janssen that will oversee the partnership and select the proposals for award. The research teams will benefit from funding, as well as access to drug development tools and expertise from Janssen.
Click here to read more about this new university-industry partnership.Share this: